Raffles Medical Group (SGX:BSL)'s 1H20 PATMI fell 38.2% y-o-y to SGD17.2m, missing our/ consensus forecasts amid challenging conditions due to Covid-19. Excluding China operations, PAT would have fallen only 3.7%.
We trim FY20-22E EPS by 4-5% although our DCF-based Target Price stays at SGD0.99 (WACC: 9%, LTG: 3%) as tweaks were mostly non-cash.
Due to insufficient upside, we downgrade Raffles Medical to HOLD, although we are positive towards
the returning of local patients; and
secular growth from population aging and new China hospitals.
Revenue Resilience as Raffles Medical Aids in Covid-19 Battle
Raffles Medical's 1H20 revenue fell 5.4% y-o-y to SGD241.4m. Hospital services declined 14.5% y-o-y due to deferrals for elective surgeries and fewer offshore patients. This was cushioned by a 6.8% increase in healthcare services division from services to tackle Covid-19 in Singapore (e.g. air-border screening, swabbing of foreign workers, etc).
Revenue was also shored up by government-subsidised patients to keep public hospital capacity for Covid-19 patients. Raffles Medical has also obtained a licence for Covid-19 PCR and serology testing.
Local Patients Are Returning
In Jun-20, all key services resumed with the relaxation of the circuit breaker and local patient volumes are beginning to recover to pre-Covid- 19 levels. If conditions permit, Raffles Medical is keen to open Raffles Hospital Shanghai within this year, or in early FY21. Raffles Hospital Chongqing’s EBITDA loss run-rate is still expected to be contained within SGD2-3m per quarter (comparable to FY19).
Return of Foreign Patients Is the Key Swing Factor
Our new FY20E PATMI assumes a 38% h-o-h recovery, largely driven by the normalisation of local volumes, but offset by reduced government wage support and tapering in revenue from Covid-19-related services.
In our view, the key swing factor for Raffles Medical’s recovery profile is how quickly foreign patient revenue (around 25-30%) can be regained. We see the return of lockdown measures as a key earnings downside risk.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....